Dr Reddy I Slayback Pharma
Dr Reddy’s lab enters into a licensing agreement for OTC ophthalmic product for U.S market
Hyderabad/IBNS: Indian drugmaker Dr. Reddy’s Laboratories has entered into a licensing agreement with New Jersey-based Slayback Pharma LLC to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025 percent.
Slayback Pharma is the first company to file an abbreviated new drug application (ANDA) for the private label equivalent for Lumify with the USFDA under Paragraph IV certification.
The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025 percent in 2.5 ml and 7.5 ml fill volumes.
Lumify, a trademark of Bausch & Lomb, is an Over-The-counter (OTC) eye drop that can be used to relieve redness of the eye due to minor eye irritations.
The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S, Hyderabad-based pharma giant said in a release here on Saturday.
Marc Kikuchi, CEO for North America Generics at Dr. Reddy’s, said: “We are pleased to license this important OTC ophthalmic product for the U.S. market."
“This product complements Dr. Reddy’s growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday® Once Daily Relief and Pataday® Twice Daily Relief,” he said.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
